Market Exclusive

Analyst Upgrades – Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Gets Upgraded By William Blair from Market Perform to Outperform

Analyst Ratings For Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Today, Arrowhead Pharmaceuticals (NASDAQ:ARWR) stock received an upgrade by William Blair from Market Perform to Outperform.

There are 4 hold ratings, 1 buy rating on the stock.

The current consensus rating on Arrowhead Pharmaceuticals (NASDAQ:ARWR) is Hold (Score: 2.20) with a consensus target price of $2.00 per share, a potential 39.58% downside.

Some recent analyst ratings include

Recent Insider Trading Activity For Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Arrowhead Pharmaceuticals (NASDAQ:ARWR) has insider ownership of 4.57% and institutional ownership of 20.61%.

Recent Trading Activity for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Shares of Arrowhead Pharmaceuticals closed the previous trading session at with shares trading hands.

Exit mobile version